Mathew P. Martin

发表

Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains.

S. Olesen, E. Schönbrunn, Mathew P. Martin, 2013, ACS chemical biology.

Discovery of a potential allosteric ligand binding site in CDK2.

Huijong Han, E. Schönbrunn, Mathew P. Martin, 2011, ACS chemical biology.

Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors

S. Olesen, A. Becker, E. Schönbrunn, 2014, ACS chemical biology.

A Novel Approach to the Discovery of Small‐Molecule Ligands of CDK2

E. Schönbrunn, Mathew P. Martin, S. Betzi, 2012, Chembiochem : a European journal of chemical biology.

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease

James D. Firth, Hanna F. Klein, M. Noble, 2020, Nature Communications.

FragLites-Minimal, Halogenated Fragments Displaying Pharmacophore Doublets. An Efficient Approach to Druggability Assessment and Hit Generation.

M. Noble, J. Endicott, M. Waring, 2019, Journal of medicinal chemistry.

CDK1 structures reveal conserved and unique features of the essential cell cycle CDK

Jane A. Endicott, N. Brown, M. Noble, 2015, Nature Communications.

Supplemental Information Identi fi cation and Characterization of an Irreversible Inhibitor of CDK 2

Noble, J. Endicott, M. Geitmann, 2022 .

Stability of the Human Hsp90-p50Cdc37 Chaperone Complex against Nucleotides and Hsp90 Inhibitors, and the Influence of Phosphorylation by Casein Kinase 2

S. Olesen, E. Schönbrunn, Mathew P. Martin, 2015, Molecules.

Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor

Nathan Brown, Julian Blagg, Paul Workman, 2018, Molecular oncology.

Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4.

M. Noble, J. Endicott, S. Cook, 2019, European journal of medicinal chemistry.

Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2).

W. Guida, E. Schönbrunn, S. Sebti, 2012, MedChemComm.

Structure-based discovery and development of cyclin-dependent protein kinase inhibitors

M. Noble, J. Endicott, Mathew P. Martin, 2018 .

Molecular profiling and combinatorial activity of CCT068127

M. Noble, P. Workman, S. Whittaker, 2017 .

Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8ob00099a

M. Noble, J. Endicott, I. Hardcastle, 2018, Organic & biomolecular chemistry.

A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia

J. Allan, O. Heidenreich, M. Trost, 2022, Journal of medicinal chemistry.

Build–Couple–Transform: A Paradigm for Lead-like Library Synthesis with Scaffold Diversity

M. Noble, B. Golding, Mathew P. Martin, 2022, Journal of medicinal chemistry.

Comparative Analyses of Poly(ADP-Ribose) Polymerase Inhibitors

Mathew P. Martin, M. Guha, Wenyue Hu, 2022, International journal of toxicology.

Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor

M. Noble, J. Endicott, S. Cook, 2022, Journal of medicinal chemistry.

Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.

A. Becker, C. Cubitt, Huijong Han, 2013, Journal of medicinal chemistry.

RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.

Ying Sun, E. Schönbrunn, S. Sebti, 2012, Cancer research.

Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition

M. Noble, J. Endicott, Lan Z. Wang, 2019, Cell chemical biology.

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines

M. Noble, J. Endicott, I. Hardcastle, 2016, Journal of medicinal chemistry.

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure−Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substitued 2-Arylaminopurines

M. Noble, J. Endicott, I. Hardcastle, 2017 .